Clinical Trial Update: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating Tafasitamab plus Lenalidomide in combination with R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Lenalidomide (lenalidomide)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)
• tafasitamab (tafasitamab)

Snippet

Sponsor: Incyte Corporation | Conditions: Diffuse Large B-cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING